81720-19-6

Basic information

• Product Name: METHYL(3-NITROPHENOXY)ACETATE
• Synonyms: METHYL(3-NITROPHENOXY)ACETATE
• CAS NO: 81720-19-6
• Molecular Formula: C₉H₉NO₅
• Molecular Weight: 211.17
• Mol File: 81720-19-6.mol
• Article Data: 19

Chemical Properties

• Appearance: /
• CAS DataBase Reference: METHYL(3-NITROPHENOXY)ACETATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL(3-NITROPHENOXY)ACETATE(81720-19-6)
• EPA Substance Registry System: METHYL(3-NITROPHENOXY)ACETATE(81720-19-6)

Safety Data

• Hazardous Substances Data: 81720-19-6(Hazardous Substances Data)

Upstream product

• 554-84-7 meta-nitrophenol 
• 96-32-2 bromoacetic acid methyl ester 
• 1878-88-2 2-(3-nitrophenoxy)acetic acid 
• 96-34-4 methyl chloroacetate 
• 67-56-1 methanol 
• 3019-85-0 sodium 3-nitrophenoxide 
• 105-39-5 chloroacetic acid ethyl ester 
• 40257-02-1 3-nitrophenoxyacetyl chloride 

Downstream Products

• 36304-45-7 (3-nitrophenoxy)acetic acid hydrazide 
• 1092938-95-8 methyl {3-[(5-bromo-6-phenylfuro[2,3-d]pyrimidin-4-yl)amino]phenoxy}acetate 
• 1092938-69-6 (3-{[5-(4-Ethylcyclohex-1-en-1-yl)-6-phenylfuro[2,3-d]pyrimidin-4-yl]amino}phenoxy)acetic acid 
• 1092938-75-4 (3-{[5-(5-Ethylpyridin-2-yl)-6-phenylfuro[2,3-d]pyrimidin-4-yl]amino}phenoxy)acetic acid 
• 916737-63-8 3-(3-methyl-1,2,4-oxadiazol-5-yl)methyloxyaniline 
• 421568-37-8 1-(3-methyl-1,2,4-oxadiazol-5-yl)methyloxy-3-nitrobenzene 
• 1092938-73-2 methyl (3-{[5-(5-ethylpyridin-2-yl)-6-phenylfuro[2,3-d]pyrimidin-4-yl]amino}phenoxy)acetate 
• 943345-07-1 3-{[5-(4-methoxyphenyl)-6-phenylfuro[2,3-d]pyrimidin-4-yl]amino}phenoxyacetic acid 2-amino-2-hydroxymethyl-1,3-propanediol 
• 943345-14-0 5-(4-Methoxyphenyl)-6-phenyl-N-[3-(1H-tetrazol-5-ylmethoxy)phenyl]furo[2,3-d]pyrimidin-4-amine 
• 943345-02-6 3-{[5-(4-fluorophenyl)-6-phenylfuro[2,3-d]pyrimidin-4-yl]amino}phenoxyacetic acid methyl ester 
• 943345-03-7 3-{[5-(4-Fluorophenyl)-6-phenylfuro[2,3-d]pyrimidin-4-yl]amino}phenoxyacetic acid 
• 943344-66-9 2-(3-{[5-(4-methoxyphenyl)-6-phenylfuro[2,3-d]pyrimidin-4-yl]amino}phenoxy)acetamide 
• 943344-68-1 (3-{[5-(4-Methoxyphenyl)-6-phenylfuro[2,3-d]pyrimidin-4-yl]amino}phenoxy)acetonitrile 
• 943345-15-1 (3-{[5-(4-Hydroxyphenyl)-6-phenylfuro[2,3-d]pyrimidin-4-yl]amino}phenoxy)acetic acid 

Relevant articles and documents

Design, synthesis, and biological studies of novel 3-benzamidobenzoic acid derivatives as farnesoid X receptor partial agonist

Farnesoid X receptor (FXR), a bile acid-activated nuclear receptor, regulates the metabolism of bile acid and lipids as well as maintains the stability of internal environment. FXR was considered as a therapeutic target of liver disorders, such as drug-induced liver injury, fatty liver and cholestasis. The previous reported FXR partial agonist 6 was a suitable lead compound in terms of its high potent and low molecular size, while the docking study of compound 6 suggested a large unoccupied hydrophobic pocket, which might be provided more possibility of structure-activity relationship (SAR) study. In this study, we have performed comprehensive SAR and molecular modeling studies based on lead compound 6. All of these efforts resulted in the identification of a novel series of FXR partial agonists. In this series, compound 41 revealed the best activity and strong interaction with binding pocket of FXR. Moreover, compound 41 protected mice against acetaminophen-induced hepatotoxicity by the regulation of FXR-related gene expression and improving antioxidant capacity. In summary, these results suggest that compound 41 is a promising FXR partial agonist suitable for further investigation.

SUBSTITUTED AMIDE COMPOUNDS USEFUL AS FARNESOID X RECEPTOR MODULATORS

Disclosed are compounds of Formula (I): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein Q is: (i) halo, cyano, hydroxyl, NRxRx, C(O)OH, C(O)NH2, C1-6 alkyl substituted with zero to 6 R1a, or P(O)R1cR1c; or (ii) L R1; and A, X1, X2, X3, X4, Z1, Z2, R1, R1a, R1c, R2, R3a, R3b, Rx, L, a, b, and d are defined herein. Also disclosed are methods of using these compounds to modulate the activity of farnesoid X receptor (FXR); pharmaceutical compositions comprising these compounds; and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

Pyrrolidinyl phenylurea derivatives as novel CCR3 antagonists

Optimization starting with our lead compound 1 (IC50 = 4.9 nM) led to the identification of pyrrolidinyl phenylurea derivatives. Further modification toward improvement of the bioavailability provided (R)-1-(1-((6-fluoronaphthalen-2-yl)methyl)pyrrolidin-3-yl)-3-(2-(2- hydroxyethoxy)phenyl)urea 32 (IC50 = 1.7 nM), a potent and orally active CCR3 antagonist.